NPM1 and acute myeloid leukemia: Although the NPM1 mutation is considered a good prognosticmarker, even in this scenario, the 5-year rate of NPM1-mutated casesis below 50% overall survival and the crude numbers of deceased AMLpatients harbor NPM1 mutation, mainly due to the high incidence ofthis genetic alteration.51 Due to its biologicaland clinical characteristics, AML with NPM1 mutation was recognizedin 2017 as a distinct entity in the WHO classification of hematopoieticmalignancies.